{"entity":{"id":"tub-030","kind":"drug","name":"TUB-030","aka":[],"tldr":"TUB-030 is an experimental antibody-drug conjugate from Tubulis (Gilead), in phase 1 trials for advanced solid tumours, head and neck squamous cell carcinoma and small cell lung cancer and other cancers.","summary":"TUB-030 is an antibody-drug conjugate from Tubulis (Gilead), with Gilead Sciences as acquirer. An IgG1 antibody against 5T4 joined to the topoisomerase I inhibitor exatecan through a cleavable linker made with P5 conjugation, with a drug-to-antibody ratio of 8. Its furthest stage is phase 1, for advanced solid tumours, head and neck squamous cell carcinoma, small cell lung cancer and non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. Tubulis pipeline page: Phase I/IIa study 5-STAR 1-01 (NCT06657222), status shown as Phase 1; recruiting per registry. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Tubulis (Gilead): tubulis.com","url":"https://tubulis.com/our-pipeline/"},{"label":"Tubulis (Gilead): tubulis.com","url":"https://tubulis.com/our-pipeline/"},{"label":"Tubulis (Gilead): tubulis.com","url":"https://tubulis.com/news/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline/"},{"label":"ClinicalTrials.gov: trials of TUB-030","url":"https://clinicaltrials.gov/search?intr=TUB-030"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","sclc","nsclc","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["tubulis"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06657222"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"TUB-030","modality":"Antibody-drug conjugate","mechanism":"An IgG1 antibody against 5T4 joined to the topoisomerase I inhibitor exatecan through a cleavable linker made with P5 conjugation, with a drug-to-antibody ratio of 8.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tub-030/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/"}],"trial":[{"id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","route":"/trials/nct06657222/"}]}}